細胞免疫療法の世界市場レポート 2025年

細胞免疫療法の市場規模は今後数年で急成長が見込まれます。2029年には112億7,000万米ドルに成長し、CAGRは14.2％となります。予測期間の成長は、固形がんへの拡大、製造の改善、ヘルスケアインフラ、研究資金に起因します。予測期間の主な動向は、研究開発投資、臨床試験データ、併用療法などです。

細胞免疫療法市場の成長は、この分野における研究の増加と臨床試験の成功によって推進されています。企業はさまざまな疾患に対処するため、新たな細胞免疫療法の開発に専念しています。2022年4月現在、世界で有効な細胞治療薬は2,756品目で、2021年から36%増加しており、この分野の急速な成長を示しています。特に臨床および前臨床段階でのこの成長は、市場情勢を拡大し、市場収益を押し上げると予想されます。

がんの蔓延も細胞免疫療法市場の成長を促進すると予想される要因の一つです。がんは、制御不能な細胞増殖を特徴とする疾患群であり、細胞免疫療法を含むがん治療法の研究と投資に拍車をかけています。これらの治療法は、患者の免疫システムを活用してがん細胞と闘うものであり、細胞免疫療法の増加に寄与しています。例えば、英国におけるがん患者数は、現在の300万人から2025年には350万人、2030年には400万人、2040年には530万人に増加すると予測されています。このような有病率の増加は、がん治療、治療オプション、支援サービスの改善に対する需要の増加を浮き彫りにし、ヘルスケアと医薬品市場の進歩と成長を促進しています。このことは、効果的ながん治療に対する需要の高まりを浮き彫りにし、細胞免疫療法市場をさらに押し上げています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の細胞免疫療法市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の細胞免疫療法市場：成長率分析
• 世界の細胞免疫療法市場の実績：規模と成長、2019～2024年
• 世界の細胞免疫療法市場の予測：規模と成長、2024～2029年、2034年
• 世界の細胞免疫療法総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の細胞免疫療法市場：療法別、実績と予測、2019～2024年、2024～2029年、2034年
• 腫瘍浸潤リンパ球（TIL）療法
• 改変T細胞受容体（TCR）療法
• キメラ抗原受容体（CAR）T細胞療法
• ナチュラルキラー（NK）細胞療法
• 世界の細胞免疫療法市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• B細胞悪性腫瘍
• 前立腺がん
• 腎細胞がん
• 肝臓がん
• 非ホジキンリンパ腫
• その他
• 世界の細胞免疫療法市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 前立腺がん
• 乳がん
• 皮膚がん
• 卵巣がん
• 脳腫瘍
• 肺がん
• その他
• 世界の細胞免疫療法市場：腫瘍浸潤リンパ球（TIL）療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 自家TIL療法
• 同種TIL療法
• その他のTIL療法
• 世界の細胞免疫療法市場：改変T細胞受容体（TCR）療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アルファベータTCR療法
• ガンマデルタTCR療法
• その他の人工TCR療法
• 世界の細胞免疫療法市場：キメラ抗原受容体（CAR）T細胞療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 自家CAR T細胞療法
• 同種CAR-T細胞療法
• 固形腫瘍に対するCAR-T細胞療法
• 造血悪性腫瘍に対するCAR-T細胞療法
• その他のCAR-T細胞療法
• 世界の細胞免疫療法市場：ナチュラルキラー（NK）細胞療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 自家NK細胞療法
• 同種NK細胞療法
• 改変を加えたNK細胞療法
• その他のNK細胞療法

第7章 地域別・国別分析

• 世界の細胞免疫療法市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の細胞免疫療法市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 細胞免疫療法市場：競合情勢
• 細胞免疫療法市場：企業プロファイル
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Apac Biotech Overview, Products and Services, Strategy and Financial Analysis
  • Dendreon Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
  • JW CreaGene Co. Ltd Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Green Cross Corp
• AstraZeneca plc
• Bristol Myers Squibb Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Adicet Bio Inc.
• ResTORbio Inc.
• Celyad SA
• Merck KGaA
• GlaxoSmithKline plc
• Johnson & Johnson
• Adaptimmune Therapeutics plc
• AVROBIO Inc.
• Cellular Biomedicine Group Inc.
• Kite Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 細胞免疫療法市場2029：新たな機会を提供する国
• 細胞免疫療法市場2029：新たな機会を提供するセグメント
• 細胞免疫療法市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cellular immunotherapy represents an innovative approach to immunotherapy where patients are administered T cells, a type of immune cell, to assist the body in combating diseases such as cancer. It harnesses the body's immune system to fight against cancer.

The key therapies within cellular immunotherapy include tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a form of adoptive cellular therapy involving the extraction of lymphocytes that have infiltrated tumors, their cultivation and amplification in vitro, and subsequent infusion into patients for therapeutic purposes. This therapy finds application in various primary indications, including b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, among others, and is utilized in the treatment of conditions such as prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumors, lung cancer, and more.

The cellular immunotherapy market research report is one of a series of new reports from The Business Research Company that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cellular immunotherapy market size has grown rapidly in recent years. It will grow from $5.72 billion in 2024 to $6.61 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to cancer treatment advancements, clinical success stories, regulatory approvals, growing incidence of targeted diseases.

The cellular immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $11.27 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to expansion to solid tumors, improved manufacturing, healthcare infrastructure, research funding. Major trends in the forecast period include research and development investments, clinical trial data, combination therapies.

The growth of the cellular immunotherapy market is being propelled by increasing research and successful clinical trials in the field. Companies are dedicated to developing new cellular immunotherapies to address various diseases. As of April 2022, there were 2,756 active cell therapy drugs globally, a 36% increase from 2021, indicating rapid growth in this sector. This growth, particularly in clinical and preclinical stages, is expected to expand the cellular immunotherapy landscape, driving market revenues higher.

The prevalence of cancer is another factor expected to drive the growth of the cellular immunotherapy market. Cancer is a group of diseases characterized by uncontrolled cell growth, spurring research and investment in cancer therapies, including cellular immunotherapies. These therapies leverage the patient's immune system to combat cancer cells, contributing to the rise of cellular immunotherapies. For instance, the estimated number of people living with cancer in the UK is projected to rise from the current 3 million to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. This growing prevalence highlights the increasing demand for improved cancer care, treatment options, and supportive services, driving advancements and growth in the healthcare and pharmaceutical markets. This underscores the growing demand for effective cancer treatments, further boosting the cellular immunotherapy market.

Companies in the cellular immunotherapy market are focusing on the development of off-the-shelf allogeneic therapies to improve cancer treatment. These therapies use donor cells rather than the patient's cells, offering benefits such as cost-effectiveness, large-scale production, speed, and quality control. Novartis, for example, received expedited FDA approval for Kymriah to treat adult patients with relapsed or refractory follicular lymphoma. Acepodia initiated a phase 1 clinical trial for ACE1702, an allogeneic, off-the-shelf NK cell therapy to treat solid tumors.

Major companies in the cellular immunotherapy market are focusing on technological advancements, such as innovative immunotherapies, to enhance treatment efficacy and broaden their applications. This includes developments in personalized medicine, combination therapies, and scalable manufacturing processes to improve patient outcomes. Immunotherapy is a treatment that leverages the body's immune system to combat diseases like cancer, either by boosting immune responses or employing targeted therapies to focus immune activity on specific cells. For instance, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider, introduced CAR-T cell therapy. This groundbreaking cancer treatment employs genetically engineered T cells designed to target and destroy cancer cells, providing a highly personalized approach. CAR-T cell therapy has shown remarkable effectiveness in achieving durable remission rates, particularly in treatment-resistant blood cancers, while minimizing harm to healthy tissues.

In January 2023, AstraZeneca, a UK-based pharmaceutical company, acquired Neogene Therapeutics for an undisclosed amount. This strategic acquisition aims to bolster AstraZeneca's oncology portfolio by advancing the development of innovative T-cell receptor therapies for solid tumors. Neogene Therapeutics, a US-based biotechnology company, specializes in personalized cellular immunotherapy by engineering T-cells to target specific cancer cells, offering a promising approach to treating various types of cancer.

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd., Green Cross Corp, AstraZeneca PLC, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics PLC, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

North America was the largest region in the cellular immunotherapy market in 2024. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cellular Immunotherapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cellular immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cellular immunotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cellular immunotherapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy; Engineered T Cell Receptor (TCR) Therapy; Chimeric Antigen Receptor (CAR) T Cell Therapy; Natural Killer (NK) Cell Therapy
• 2) By Primary Indication: B-cell Malignancies; Prostate Cancer; Renal Cell Carcinoma; Liver Cancer; Non-Hodgkin lymphoma; Other Primary Indications
• 3) By Application: Prostate Cancer; Breast Cancer; Skin Cancer; Ovarian Cancer; Brain Tumor; Lung Cancer; Other Applications
• Subsegments:
• 1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy; Allogeneic TIL Therapy; Other TIL Therapy
• 2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy; Gamma-Delta TCR Therapy; Other Engineered TCR Therapy
• 3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy; Allogeneic CAR T Cell Therapy; CAR T Cell Therapy For Solid Tumors; CAR T Cell Therapy For Hematologic Malignancies; Other CAR T Cell Therapy
• 4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy; Allogeneic NK Cell Therapy; NK Cell Therapy With Engineered Modifications; Other NK Cell Therapy
• Companies Mentioned: Novartis International AG; Gilead Sciences Inc.; Apac Biotech; Dendreon Pharmaceuticals LLC; JW CreaGene Co. Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cellular Immunotherapy Market Characteristics

3. Cellular Immunotherapy Market Trends And Strategies

4. Cellular Immunotherapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cellular Immunotherapy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cellular Immunotherapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cellular Immunotherapy Market Growth Rate Analysis
• 5.4. Global Cellular Immunotherapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cellular Immunotherapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cellular Immunotherapy Total Addressable Market (TAM)

6. Cellular Immunotherapy Market Segmentation

• 6.1. Global Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor-Infiltrating Lymphocyte (TIL) Therapy
• Engineered T Cell Receptor (TCR) Therapy
• Chimeric Antigen Receptor (CAR) T Cell Therapy
• Natural Killer (NK) Cell Therapy
• 6.2. Global Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• B-cell Malignancies
• Prostate Cancer
• Renal Cell Carcinoma
• Liver Cancer
• Non-Hodgkin Lymphoma
• Other Primary Indications
• 6.3. Global Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prostate Cancer
• Breast Cancer
• Skin Cancer
• Ovarian Cancer
• Brain Tumor
• Lung Cancer
• Other Applications
• 6.4. Global Cellular Immunotherapy Market, Sub-Segmentation Of Tumour-Infiltrating Lymphocyte (TIL) Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous TIL Therapy
• Allogeneic TIL Therapy
• Other TIL Therapy
• 6.5. Global Cellular Immunotherapy Market, Sub-Segmentation Of Engineered T Cell Receptor (TCR) Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha-Beta TCR Therapy
• Gamma-Delta TCR Therapy
• Other Engineered TCR Therapy
• 6.6. Global Cellular Immunotherapy Market, Sub-Segmentation Of Chimeric Antigen Receptor (CAR) T Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous CAR T Cell Therapy
• Allogeneic CAR T Cell Therapy
• CAR T Cell Therapy For Solid Tumors
• CAR T Cell Therapy For Hematologic Malignancies
• Other CAR T Cell Therapy
• 6.7. Global Cellular Immunotherapy Market, Sub-Segmentation Of Natural Killer (NK) Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous NK Cell Therapy
• Allogeneic NK Cell Therapy
• NK Cell Therapy With Engineered Modifications
• Other NK Cell Therapy

7. Cellular Immunotherapy Market Regional And Country Analysis

• 7.1. Global Cellular Immunotherapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cellular Immunotherapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cellular Immunotherapy Market

• 8.1. Asia-Pacific Cellular Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cellular Immunotherapy Market

• 9.1. China Cellular Immunotherapy Market Overview
• 9.2. China Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cellular Immunotherapy Market

• 10.1. India Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cellular Immunotherapy Market

• 11.1. Japan Cellular Immunotherapy Market Overview
• 11.2. Japan Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cellular Immunotherapy Market

• 12.1. Australia Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cellular Immunotherapy Market

• 13.1. Indonesia Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cellular Immunotherapy Market

• 14.1. South Korea Cellular Immunotherapy Market Overview
• 14.2. South Korea Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cellular Immunotherapy Market

• 15.1. Western Europe Cellular Immunotherapy Market Overview
• 15.2. Western Europe Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cellular Immunotherapy Market

• 16.1. UK Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cellular Immunotherapy Market

• 17.1. Germany Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cellular Immunotherapy Market

• 18.1. France Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cellular Immunotherapy Market

• 19.1. Italy Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cellular Immunotherapy Market

• 20.1. Spain Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cellular Immunotherapy Market

• 21.1. Eastern Europe Cellular Immunotherapy Market Overview
• 21.2. Eastern Europe Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cellular Immunotherapy Market

• 22.1. Russia Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cellular Immunotherapy Market

• 23.1. North America Cellular Immunotherapy Market Overview
• 23.2. North America Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cellular Immunotherapy Market

• 24.1. USA Cellular Immunotherapy Market Overview
• 24.2. USA Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cellular Immunotherapy Market

• 25.1. Canada Cellular Immunotherapy Market Overview
• 25.2. Canada Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cellular Immunotherapy Market

• 26.1. South America Cellular Immunotherapy Market Overview
• 26.2. South America Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cellular Immunotherapy Market

• 27.1. Brazil Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cellular Immunotherapy Market

• 28.1. Middle East Cellular Immunotherapy Market Overview
• 28.2. Middle East Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cellular Immunotherapy Market

• 29.1. Africa Cellular Immunotherapy Market Overview
• 29.2. Africa Cellular Immunotherapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cellular Immunotherapy Market, Segmentation By Primary Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cellular Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cellular Immunotherapy Market Competitive Landscape And Company Profiles

• 30.1. Cellular Immunotherapy Market Competitive Landscape
• 30.2. Cellular Immunotherapy Market Company Profiles
  • 30.2.1. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Apac Biotech Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Dendreon Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. JW CreaGene Co. Ltd Overview, Products and Services, Strategy and Financial Analysis

31. Cellular Immunotherapy Market Other Major And Innovative Companies

• 31.1. Green Cross Corp
• 31.2. AstraZeneca plc
• 31.3. Bristol Myers Squibb Company
• 31.4. Pfizer Inc.
• 31.5. F. Hoffmann-La Roche Ltd.
• 31.6. Adicet Bio Inc.
• 31.7. ResTORbio Inc.
• 31.8. Celyad SA
• 31.9. Merck KGaA
• 31.10. GlaxoSmithKline plc
• 31.11. Johnson & Johnson
• 31.12. Adaptimmune Therapeutics plc
• 31.13. AVROBIO Inc.
• 31.14. Cellular Biomedicine Group Inc.
• 31.15. Kite Pharma Inc.

32. Global Cellular Immunotherapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cellular Immunotherapy Market

34. Recent Developments In The Cellular Immunotherapy Market

35. Cellular Immunotherapy Market High Potential Countries, Segments and Strategies

• 35.1 Cellular Immunotherapy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cellular Immunotherapy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cellular Immunotherapy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer